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Background/objective: Outcomes of treatment for multidrug-resistant tuberculosis (MDR-TB)
remain poor worldwide. Among patients with MDR-TB in Belarus who started treatment in
2012, only 54% completed it successfully, with treatment failure reported in 22% of the
patients; additionally, 11% died and 13% were lost to follow-up or remained unevaluated.
In Belarus, to improve outcomes, bedaquiline was introduced in MDR-TB treatment in June
2015. The national TB program developed measures to monitor safety and effectiveness of
bedaquiline-containing regimens in line with the World Health Organization recommenda-
tions.
Methods: After enrollment of patients, clinical, radiological, laboratory, and microbiological
data were carefully collected at start, during treatment, and at follow-up. A total of 197
patients were enrolled: male, 140 (71%); female, 57 (29%); new TB cases, 83 (42%); previously
treated, 114 (58%); extensively drug-resistant-TB (XDR-TB), 128 (65%), pre-XDR-TB (fluoro-
quinolone resistant), 34 (17%), pre-XDR-TB (injectables resistant), 25 (13%), and other
MDR-TB cases, 10 (5%).
Results: According to the intermediate analysis, 186 patients currently are continuing with
the treatment, two patients died, and nine patients were lost to follow-up. Sputum culture
conversion were observed in 186 patients (94%) at 6 months and one (0.5%) of these 197
patients started treatment; six patients (3%) remain sputum culture positive. The safety
data were as follows: 135 patients (68%) experienced metabolism and nutrition disorders
(hyperuricemia being the most common), 127 patients (64%) experienced hepatobiliary dis-
orders (hepatic functions abnormality being the most common), 93 patients (47%) experi-
enced electrolyte disorders (hypomagnesemia being the most common), 80 patients
(41%) experienced cardiac disorders (abnormal electrocardiogram and arrhythmia being
the most common), 68 patients (35%) experienced gastrointestinal system disorders (nau-
sea, vomiting, and abdominal pain being the most common disorders), 54 patients (27%)
experienced blood and the lymphatic system disorders (low platelet count being the most
common), 42 patients (21%) experienced renal and urinary disorders (creatinine clearancet. J. Myco-
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(headache, dizziness, and paresthesia being the most common ones), 36 patients (18%)
experienced skin and subcutaneous tissue disorders (rush and pruritus being the most
common), 35 patients (17%) experienced ear and labyrinth disorders (tinnitus and
decreased hearing being the most common ones), 32 patients (15%) experienced psychiatric
disorders (insomnia being the most common disorder), and 30 patients (14%) experienced
infections and infestations (candidiasis being the most common). The most adverse events
were mild or moderate in severity and reversible. One death was possibly related to MDR-
TB therapy.
Conclusion: Our interim results on safety and effectiveness of bedaquiline-containing regi-
mens in multidrug and extensively drug-resistant tuberculosis (M/XDR-TB) patients are
encouraging. They will add value to understanding role and place of this new anti-TB drug
in M/XDR-TB treatment.Conflicts of interest
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